Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
August 28th, 2021
4.2K views
The protocol aims to introduce the use of a triple quadrupole mass spectrometer for Multiple Reaction Monitoring (MRM) of proteins from clinical samples. We have provided a systematic workflow starting from sample preparation to data analysis for clinical samples with all the necessary precautions to be taken.
Overview
This study introduces a systematic workflow for the use of Multiple Reaction Monitoring (MRM) to detect and quantify proteins from clinical samples, specifically human brain tissue. The protocol encompasses steps from sample preparation to data analysis, emphasizing the avoidance of contaminants to ensure accurate measurements.
Key Study Components
Research Area
- Proteomics
- Clinical diagnostics
- Mass spectrometry
Background
- Targeted proteomic approaches are crucial for validating protein expression changes.
- MRM is a sensitive method for quantifying proteins in biological samples.
- Importance of sample purity and preparation in proteomic analyses.
Methods Used
- Sample preparation including tissue lysis and protein digestion
- Use of human brain tissue
- Mass spectrometry and MRM techniques
Main Results
- Successfully detailed a stepwise protocol for protein quantification via MRM.
- Highlighted the importance of proper sample handling to reduce contamination.
- Demonstrated the application of various assays to prepare for mass spectrometry.
Conclusions
- This study illustrates an effective workflow for MRM-based protein analysis from clinical samples.
- This approach can enhance biomarker discovery in clinical proteomics.
Frequently Asked Questions
What is Multiple Reaction Monitoring (MRM)?
MRM is a targeted mass spectrometry technique used for detecting and quantifying specific proteins in complex biological samples.
Why is sample preparation crucial in proteomics?
Sample preparation minimizes contaminants and ensures reliable and accurate quantification of proteins.
What types of samples are suitable for MRM?
Clinical samples, including tissues like human brain, are ideal for MRM analyses.
How does the Bradford Assay work?
The Bradford Assay estimates protein concentration based on the binding of Coomassie Brilliant Blue dye to proteins.
What role does mass spectrometry play in proteomics?
Mass spectrometry provides high sensitivity and specificity for protein identification and quantification.
What is a transition list in the context of MRM?
A transition list contains information about precursor and product ions essential for the mass spectrometer to monitor specific reactions.
Can MRM be used for other types of biological samples?
Yes, MRM can be applied to various biological samples beyond clinical tissues, including serum, urine, and cell cultures.
Executive Industry Relevance
Targeted proteomics using MRM enables precise quantification of proteins in complex biological matrices, supporting hypothesis-driven target validation in neuroscience drug discovery. This workflow addresses the limitations of low-throughput antibody-based methods and shotgun proteomics by delivering reproducible, quantitative data essential for biomarker identification and mechanistic de-risking in CNS therapeutic development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by quantifying specific proteins such as Apolipoprotein A-1, Vimentin, and Nicotinamide phosphoribosyltransferase in human brain tissue.
- Operational Value: Provides a reproducible, targeted approach to validate protein expression changes from discovery-phase experiments.
Screening & Assay Development
- Scientific Value: Generates standardized, quantitative peptide measurements via MRM, enabling reliable compound evaluation in screening cascades.
- Operational Value: Supports assay standardization through transition list optimization and instrument QC protocols, enhancing reproducibility across runs.
Translational & Preclinical Research
- Scientific Value: Facilitates translational biomarker alignment by detecting disease-relevant proteins in human brain tissue with high specificity.
- Operational Value: Enables risk-adjusted advancement decisions through consistent, quantifiable protein readouts across experimental conditions.
Pipeline & Workflow Integration
This MRM workflow integrates into the discovery continuum from target validation through lead identification, supporting data-driven decisions in preclinical research.
- Discovery Biology: Supports hypothesis testing and pathway clarification by quantifying predefined protein targets in complex tissue lysates.
- Screening: Delivers assay readiness and quantitative outputs via optimized LC-MRM methods, enabling reliable compound screening.
- Analytics: Generates fold change and adjusted P values through group comparison in Skyline, facilitating condition-to-condition comparisons.
- Translational Research: Connects discovery to preclinical continuity by measuring human brain-derived proteins with relevance to neurological disease pathways.
- Enterprise Reuse: Establishes a reusable, standardized platform for targeted protein quantification applicable across multiple CNS projects.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence through specific, quantitative protein measurements that reduce mechanistic ambiguity in target validation.
- Operational Value: Enhances standardization and scalability via defined sample preparation, transition list parameters, and instrument QC procedures.
- Strategic Value: Improves go/no-go decisions by providing reproducible protein quantification data, reducing late-stage biological risk in CNS programs.
- Portfolio Impact: Enables risk-adjusted prioritization through quantitative biomarker patterns that distinguish clinical conditions.
Implementation Considerations
- Requires expertise in proteomics sample preparation, mass spectrometry operation, and Skyline-based data analysis.
- Dependent on access to a triple quadrupole mass spectrometer (e.g., Thermo TSQ Altis) and compatible LC-MS infrastructure.
- Necessitates cross-team standardization of transition list creation, QC sample usage, and data annotation practices.
- Involves adaptation considerations for different tissue types, protein targets, and clinical sample matrices.
- Practical limitations include the need for extensive method optimization (e.g., LC gradient, collision energy) and the constraint of monitoring limited numbers of transitions per run.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in MRM?
Null hypothesis testing via group comparison in Skyline generates adjusted P values and fold changes, enabling statistically rigorous evaluation of protein expression differences between experimental conditions, which is essential for validating targets in discovery workflows.
How does independent variable isolation fit the discovery pipeline in MRM workflows?
Isolating independent variables such as protein concentration and digestion efficiency through standardized lysis, quantification, and trypsinization steps ensures that observed MRM signal changes reflect true biological variation rather than technical artifacts, supporting reliable target validation.
What quantitative dependent variable measurements enable in MRM-based proteomics?
Quantitative measurements such as peak area ratios and fold changes from MRM transitions enable precise tracking of protein abundance across conditions, providing the data needed for biomarker pattern development and target engagement assessment.
Why do replication requirements matter for cross-functional collaboration in MRM studies?
Replication requirements, including blank runs, QC standards, and replicate injections, ensure instrument stability and data consistency across days and users, which is critical for generating reproducible results that can be trusted by discovery, translational, and preclinical teams.
What statistical analysis capabilities are required before implementing MRM in a discovery workflow?
Implementation requires capabilities for peak integration, transition optimization using DART P values, group comparison analysis, and annotation of experimental conditions in Skyline to derive meaningful statistical outputs such as adjusted P values and fold changes for decision-making.
Chapters in this video
0:05
Introduction
0:49
Protein Extraction from Brain Tissue
2:04
Protein Quantification and Quality Check
2:32
Protein Digestion
3:58
Desalting and Peptide Quantification
5:06
Transition List Preparation of Finalised Targets
7:30
LC Parameters
8:03
MS Parameters
8:25
Run Sequence and Instrument QC
9:08
Method Refinement
10:58
Results and Conclusions
